Ranbaxy launches Ran-Tamsulosin capsules in Canada

Tamsulosin hydrochloride capsules have proven to be bio-equivalent to Flomax capsules, which is indicated for the treatment of benign prostatic hyperplasia. The total market for both generic and brand tamsulosin hydrochloride capsules in Canada is C$22 million, according to IMS figures.

Paul Drake, president of Ranbaxy Pharmaceuticals Canada, said: “RPCI’s sales team will be offering Ran-Tamsulosin immediately under the Ranbaxy label in all of the Canadian provinces that now provides another option to pharmacist for this molecule, that will be of benefit to both patients and the Canadian Health Care system.”